Feedback
Settings

Settings

Goto Application

83,837 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(NYHBQMYGNKIUIF-UUOKFMHZSA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 8,384
1.WO/2026/008743WATER-SOLUBLE POLYANIONIC POLYMER AS ADJUVANT FOR CARRIER-FORMULATED NUCLEIC ACID
WO - 08.01.2026
Int.Class A61K 39/39
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
39characterised by the immunostimulating additives, e.g. chemical adjuvants
 Appl.No PCT/EP2025/068909 Applicant SANOFI PASTEUR INC. Inventor GARÇON, Nathalie
The disclosure relates to an immunogenic composition comprising at least one water- soluble polyanionic polymer, at least one nucleic acid carrier comprising at least one cationic, or ionizable cationic, lipid, and at least one nucleic acid encoding at least one antigen.
2.WO/2026/008077MODIFIED GRNA FOR GENE EDITING USING CRISPR/CAS SYSTEM
WO - 08.01.2026
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No PCT/CN2025/107330 Applicant SHANGHAI VITALGEN BIOPHARMA CO., LTD. Inventor GUO, Lu
A modified gRNA for gene editing using CRISPR/Cas system is provided. A single guide RNA represented by the following formula (I), wherein specific segments selected from one or more of the regions of the formula comprise one or more chemical modifications is also provided.
3.WO/2026/010963METHODS FOR TREATING SSTR POSITIVE CANCER
WO - 08.01.2026
Int.Class A61K 51/08
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
51Preparations containing radioactive substances for use in therapy or testing in vivo
02characterised by the carrier
04Organic compounds
08Peptides, e.g. proteins
 Appl.No PCT/US2025/036100 Applicant RAYZEBIO, INC. Inventor FERREIRA, Denis Vasconcelos
Provided herein are methods of treating somatostatin receptor-positive, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer using 225Ac-DOTA-TATE or a pharmaceutically acceptable salt thereof.
4.WO/2026/010243BEST1 GENE EDITING METHOD USING CRISPR/CAS SYSTEM
WO - 08.01.2026
Int.Class C12N 15/10
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
10Processes for the isolation, preparation or purification of DNA or RNA
 Appl.No PCT/KR2025/009018 Applicant AAVATAR THERAPEUTICS CO.,LTD. Inventor SONG, Dong Woo
Disclosed in the present specification are a composition capable of editing an endogenous BEST1 gene in a cell genome by using a CRISPR/Cas system, and a gene editing method using same. The wild-type or mutant BEST1 gene can be edited using the composition and the editing method, and can be used in therapeutic strategies for various diseases associated with the BEST1 gene, such as macular dystrophy.
5.WO/2026/009929COMPOUND, RNA SYNTHESIS INITIATOR, AND USE THEREOF
WO - 08.01.2026
Int.Class C07H 21/02
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
02with ribosyl as saccharide radical
 Appl.No PCT/JP2025/023865 Applicant FUJIFILM CORPORATION Inventor NAKAGAWA Daisuke
The present invention addresses the problem of providing a compound that can be used as an RNA synthesis initiator having a desired transcriptional activity, an RNA synthesis initiator containing the compound, a kit, RNA, and a method for producing RNA. The present invention provides a compound represented by formula (1). In the formula, each symbol other than X1, X2, and X has a definition stated in the description, X1, X2, and X each independently represent -O- or -S-, and each X, if existing in a number more than one, may be the same or different from each other. At least one of X1, X2, and X represents -S-.
6.WO/2026/008063METHODS AND COMPOSITIONS FOR LPA GENE EDITING AND THERAPY USING CRISPR SYSTEM
WO - 08.01.2026
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No PCT/CN2025/107120 Applicant GENEDITBIO LIMITED Inventor WANG, Bang
Compositions and methods for inducing a double-stranded break (DSB) within the LPA gene, and/or modifying the LPA gene are provided. Compositions and methods for treating diseases associated with LPA are provided.
7.WO/2026/008078METHODS FOR KALLIKREIN (KLKB1) GENE EDITING
WO - 08.01.2026
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No PCT/CN2025/107350 Applicant SHANGHAI VITALGEN BIOPHARMA CO., LTD. Inventor GUO, Lu
A method for Kallikrein (KLKB1) gene editing. Specifically, it provides a composition for reducing or eliminating the expression or function of the gene products of KLKB1 gene in a cell, comprising at least one guide RNA. Wherein the guide RNA comprises a spacer sequence.
8.WO/2026/007958METHOD FOR PRODUCING INOSINE OR GUANOSINE
WO - 08.01.2026
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No PCT/CN2025/106457 Applicant LANGFANG MEIHUA BIOTECHNOLOGY DEVELOPMENT CO., LTD. Inventor XUE, Tingli
Provided is a modified bacterium for producing inosine or guanosine, comprising, compared with an unmodified bacterium, modifications in the expression control sequence of a gene encoding phosphoribosylformylglycinamidine cyclo-ligase (PurM). The modifications of the expression control sequence comprise: a) replacing the 1st nucleotide G before the ATG of the PurM gene ORF with C, the 4th nucleotide A before the ATG with T, the 7th nucleotide G before the ATG with C, and the 10th nucleotide A with T; and b) inserting a P43 promoter before the ATG in the ORF region of the purM gene. Further provided is a method for using the modified bacterium to increase the production of inosine or guanosine.
9.WO/2026/006925COMPOSITIONS AND METHODS FOR TARGETING CIRCULAR RNA TO INHIBIT TRANSLATION OF CIRCNLGN
WO - 08.01.2026
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No PCT/CA2025/050940 Applicant SUNNYBROOK RESEARCH INSTITUTE Inventor YANG, Burton B
The present application provides compositions and methods for targeting circular RNA, in particular to inhibit translation of circNlgn. Further provided is a single stranded, mixed base pair oligonucleotide ("mixmer") comprising a combination of ribonucleobases and deoxyribonucleobases, wherein the oligonucleotide comprises a sequence that is at least 80% complimentary with at least 10, at least 11, or from 11 to 15 consecutive nucleotides of the junction region of circular neuroligin RNA (circNlgn), and methods for using this mixmer as a medicine, for example, in the treatment of cardiac diseases or disorders, cancers, colitis or wounds.
10.WO/2026/006985RED-REGION DYE, SYNTHESIS METHOD THEREFOR AND USE THEREOF IN GENE SEQUENCING
WO - 08.01.2026
Int.Class C07D 405/06
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
405Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
02containing two hetero rings
06linked by a carbon chain containing only aliphatic carbon atoms
 Appl.No PCT/CN2024/103119 Applicant MGI TECH CO., LTD. Inventor JIA, Man
The present invention relates to the fields of organic chemistry, fluorescent dyes and gene sequencing. In particular, the present invention relates to a red-region dye compound and the use thereof as a fluorescent marker, and further relates to a method for preparing the compound, a nucleotide or oligonucleotide labeled with the compound, and a nucleic acid sequencing method.
# -